Usage Examples
- PMDA wants a bridging study in Japanese subjects before it will treat our EU Phase 3 as pivotal.
- The compound is ethnically insensitive, so we defended the bridging data package without running a new trial.
- Our bridging study is a pharmacokinetic comparison rather than a second efficacy trial, which is what keeps the filing date.
What is Bridging Study?
A bridging study is a clinical study run in the region where approval is sought that generates the pharmacodynamic, pharmacokinetic, or clinical data needed to extrapolate foreign pivotal trial results to that region's population.
Bridging studies exist because regulators historically demanded that foreign pivotal data be duplicated locally before approval. ICH E5(R1), which reached Step 4 on 5 February 1998, replaced blanket duplication with one targeted question: could ethnic factors, genetic and physiological (intrinsic) or cultural and environmental (extrinsic), change this medicine's safety, efficacy, dosage, or dose regimen in the new region? A bridging study answers that question with the minimum new data.
A bridging study covers only the extrapolation gap between an existing Complete Clinical Data Package and the population of the region where registration is sought. It sits inside a bridging data package, alongside the foreign pharmacokinetic, pharmacodynamic, and dose-response data already relevant to that population. A bridging study is not the remedy for a data package that fails the new region's regulatory requirements; those gaps demand additional studies of their own, assessed separately from extrapolation.
In practice, a bridging study is scoped in a meeting with the new region's authority, because that authority decides what will satisfy it. A bridging study is most often a pharmacokinetic or pharmacodynamic comparison in the target population. It escalates to a controlled clinical trial when the dose is in doubt, when medical practice or trial conduct differ materially, or when the drug class is unfamiliar in the new region.
Not to be confused with
- Bioequivalence study
- a bioequivalence study compares two products against each other; a bridging study compares one product across two populations. Bioequivalence asks whether the formulation is the same, bridging asks whether the clinical conclusion travels.
- Multi-regional clinical trial (MRCT)
- an MRCT builds the regional evidence into a single pivotal protocol under ICH E17, so no separate bridging step is needed. A bridging study is the sequential alternative, run after foreign pivotal data already exist.
- Complete Clinical Data Package
- the Complete Clinical Data Package is the full package that fulfils the new region's regulatory requirements. The bridging data package is the extrapolation-relevant subset of it, plus a bridging study if one is needed. Satisfying the first does not settle the second.
- Foreign data acceptance under 21 CFR 312.120
- 21 CFR 312.120 governs whether FDA will accept a foreign study at all, through GCP conduct and inspectability. A bridging study addresses whether accepted foreign data extrapolate to the U.S. population. Acceptance and extrapolation are separate gates.
The bridging obligation is split between the ICH extrapolation framework and the US regulations on foreign data.
What you must do
- 1Characterize the medicine's sensitivity to ethnic factors from its pharmacokinetic and pharmacodynamic properties, metabolic pathway, dose-response slope, and pharmacologic class before deciding whether a bridging study is needed; an ethnically insensitive characterization needs less bridging dataICH E5(R1) §3.1
- 2Assemble a bridging data package containing the extrapolation-relevant subset of the Complete Clinical Data Package, plus a bridging study only where the foreign efficacy or safety data cannot otherwise be extrapolatedICH E5(R1) §3.2.1
- 3Size the bridge to a single confirmatory trial where the data support it, rather than replicating the foreign programme in the new regionICH E5(R1) §3.2.2
- 4Conduct foreign studies relied on for US filing under GCP, with independent ethics committee review and freely given informed consent, and keep FDA able to validate the data through an onsite inspection21 CFR 312.120
- 5Where foreign data will be the sole basis for US marketing approval, show they are applicable to the U.S. population and U.S. medical practice, were generated by investigators of recognized competence, and are valid without an FDA inspection or verifiable by one; request a presubmission meeting21 CFR 314.106
Common mistakes
Deciding the bridging strategy after the pivotal data are locked
ICH E5(R1) §4 directs that any candidate medicine for global development be characterized as ethnically sensitive or insensitive during the early clinical phases, in human pharmacology and therapeutic exploratory studies. Teams that skip that characterization discover the in-region data requirement at filing, which adds a trial plus a full review cycle to the critical path.
Over-building the bridge
ICH E5(R1) §3.2.2 states that a single trial confirming extrapolation should suffice and should not need further replication. Sponsors who default to a full second Phase 3 in the new region fund confirmatory power the guideline never asked for, and delay the filing by the length of that trial.
Bridging efficacy and forgetting safety
an efficacy bridging study is frequently too small to characterize the adverse-event profile in the new region. ICH E5(R1) §3.2.4 notes that detecting serious adverse events in the 1% range generally needs about 300 patients, so a separate safety study may be required when the efficacy bridge cannot carry that load. Discovering this at review costs a cycle.
When This Matters
- PMDA wants a bridging study in Japanese subjects before it will treat our EU Phase 3 as pivotal.
- The compound is ethnically insensitive, so we defended the bridging data package without running a new trial.
- Our bridging study is a pharmacokinetic comparison rather than a second efficacy trial, which is what keeps the filing date.
Frequently Asked Questions
A bridging study is required when the new region's regulator concludes that foreign pivotal data cannot be extrapolated to its population without supplemental in-region data. ICH E5(R1) ties that judgement to the medicine's sensitivity to ethnic factors and to how far medical practice and trial conduct differ between the two regions.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
